BCPPs desiring an evidence-based, in-depth review of contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who are auditory and visual learners and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.
Content
The Clinical Application Series is an application-based continuing pharmacy education (CPE) activity designed to advance the knowledge and improve competency of participants through the delivery of evidence-based presentations. The interactive presentations are delivered live over two days at the AAPP Annual Meeting and provide knowledge and tools to improve the comprehensive care of patients with mental health disorders.
An application-based CPE activity requires that participants apply the information learned. In an application-based CPE activity, the learning objectives are written at a higher level in order to assess the learner's ability to use the information that is learned, at the expected level of practice of Board Certified Psychiatric Pharmacists. The examination for this product often features cases requiring that the participant apply the principles learned through the presentations.
The Clinical Application Series includes:
Online access to the recorded speakers' audio presentations synchronized with their slide presentations (presented live at AAPP 2024 April 7 and April 8 in Orlando, FL).
For pharmacists, 5 hours of ACPE credit and 5 hours of BCPP Recertification credit achieved by successfully completing the online AAPP recertification examination.
Access to the AAPP testing center with exam submission due on or before October 7, 2024.
Course Requirements
To satisfactorily complete the Clinical Application Series and receive 5 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
Abide by a confidentiality and honesty statement requiring individual completion of the Recertification education.
Complete an online assessment on or before the deadline of October 7, 2024.
Receive a passing score as determined by a panel of experts.
Completion of an activity evaluation form.
Partial credit is not available for individual topics within the programming; it is either all 5 hours of Clinical Application Series credit or none.
You will proceed through the following steps to satisfactorily complete this course:
Sign in (or create a FREE account).
Register for this course.
Complete the pre-test before starting the activity.
Review the full content of the activity and reflect upon its teachings.
Complete the post-test at the end of the activity no later than the closing activity date.
Complete the evaluation at the end of the activity.
Wait for the official review of exam questions within 4 weeks following the closing date.
Receive a passing grade (76%).
Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended,
or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat
or FoxIt
An adequate device and Internet connection:
Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent);
Memory: 4 GB;
Storage: 5 GB available;
Internet speed: 4.0 Mbps (up/down)
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Faculty Information and Disclosures
Katharine "Kaz" Joyer Nelson, MD, DFAPA Tiffany Buckley, PharmD, BCPP, BCPS Chelsea Di Polito, PharmD, BCPP Russell Spieth, MEd, PhD Kristen Ward, PharmD, BCPP
Associate Professor of Psychiatry and Behavioral Sciences
University of Minnesota Medical School
Minneapolis, MN
Affiliation/Financial Interest: I am a contributing author and review for UpToDate, an online reference for clinical professionals. I receive royalties for this work. I have authored the chapter on Pharmacotherapy for personality disorders. I have reviewed the chapters on Psychotherapy for borderline personality disorder | Psychotherapy for schizotypal personality disorder | Treatment of antisocial personality disorder
Grant/Research Support: Not specifically applicable to this presentation, but I do receive Educational Research Grant funding from the American Board of Psychiatry and Neurology for educational research unrelated to the topic of BPD treatment.
Consultant: I have provided educational consulting for compensation to potential Graduate Medical Education training sites. This work is unrelated to the topic of BPD treatment.
Other Financial or Material Support: ): I receive royalties for a book I co-edited on the topic of Schizophrenia and psychotic-spectrum disorders from Oxford University Press.
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: There is no FDA-approved medication for the treatment of any personality disorder. I will use generic drug names in my presentation and disclose that all discussion of pharmacology is off-label.
Tiffany Buckley, PharmD, BCPP, BCPS
Advanced Practice Psychiatric Pharmacist & Graduate Faculty in the MS in Medical Cannabis Science and Therapeutics
University of Maryland School of Pharmacy
Baltimore, MD
Affiliation/Financial Interest: TRB Speaks, LLC – I am the owner and am employee of a public speaking company about cannabis and mental health.
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Cannabis, cannabidiol (Epidiolex)
Chelsea Di Polito, PharmD, BCPP
Assistant Director of the Peer Review for Mental Health Drugs Program
University of Maryland School of Pharmacy
Baltimore, MD
No Relevant Financial Relationships to Disclose
Russell Spieth, MEd, PhD
Vice President of Adult Behavioral Health and Licensed Clinical Psychologist
The Centers
Cleveland, Ohio
No Relevant Financial Relationships to Disclose
Kristen Ward, PharmD, BCPP
Clinical Assistant Professor
University of Michigan College of Pharmacy
Ann Arbor, MI
No Relevant Financial Relationships to Disclose
My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: It is possible we will discuss off-label use of medication during case presentations related to pharmacogenetic testing.
Learning Objectives
Evidence-based Management of Borderline Personality Disorder
Assess the evidence for treatment options in the management of borderline personality disorder.
Apply strategies to sustain engagement of patients with personality disorders in treatment.
Design a rational treatment plan for patients with borderline personality disorder.
Role of Cannabis and Cannabidiol in the Treatment of Anxiety Disorders
Distinguish between cannabis, hemp, FDA-approved cannabinoids, and synthetic cannabinoids.
Evaluate the role of cannabis and/or cannabidiol in the treatment of anxiety disorders.
Assess the safety of cannabis and/or cannabidiol when used for the treatment of anxiety disorders.
The Good, the Bad, and the Unknown of Psychotropic Stewardship Implementation: A Focus on Antipsychotics
Provide rationale for implementation of a psychiatric pharmacist led psychotropic stewardship program for antipsychotics.
Assess possible barriers to implementing a psychotropic stewardship program for antipsychotics.
Measure the effectiveness of a psychotropic stewardship program for antipsychotics.
Addressing Ambivalence and Non-Adherence to Mental Health Treatment
Identify factors that contribute to ambivalence to mental health treatment, medication non-adherence, and misalignment between patient and provider goals.
Compare interventions that address mental health treatment ambivalence and/or medication adherence.
Recommend strategies to address ambivalence to mental health treatment and non-adherence based on patient-specific factors.
Using Pharmacogenomics to Optimize Mental Health Comprehensive Medication Management
Assess the impact of pharmacogenomic testing on patient outcomes in psychiatry.
Incorporate health literacy considerations in education to patients about mental health pharmacogenomic testing results.
Apply pharmacogenomic results to psychiatric treatment decisions in comprehensive medication management.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 5 hours of ACPE credit and 5 hours of BCPP Recertification credit by successfully completing the online Clinical Application Series examination.
The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 5 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH
Abigail Hampton, PharmD, BCPP
Clinical Pharmacy Practitioner- mental health
Kansas City Veterans Affairs
Kansas City, MO
No Relevant Financial Relationships to Disclose
Jordan Haygood, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
Medical University of South Carolina
Charleston, SC
No Relevant Financial Relationships to Disclose
Courtney A. Iuppa, PharmD, BCPP
Clinical Pharmacy Manager & Residency Program Director
Center for Behavioral Medicine
Kansas City, MO
No Relevant Financial Relationships to Disclose
Archana R. Jhawar, PharmD, BCPP
Clinical Pharmacist
Jesse Brown VAMC/ UIC College of Pharmacy
Chicago, IL
No Relevant Financial Relationships to Disclose
Dongmi Kim, PharmD, BCPP, BCPS
Assistant Clinical Professor
Fairleigh Dickinson University School of Pharmacy
Florham Park, NJ
No Relevant Financial Relationships to Disclose
Jamie C. Kneebusch, PharmD, BCPP, BCPS
Assistant Clinical Faculty
UC San Diego, Skaggs School of Pharmacy
La Jolla, CA
No Relevant Financial Relationships to Disclose
Linda D. Logan, PharmD, BCACP, BCPP, BCPS
Public Service Associate
University of Georgia
Athens, GA
Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, UGA Mental Health Seed Grants for MHFA and Virtual Dementia Tour, UGA College Pharmacy Ansel Fund
Megan Maroney, PharmD, BCPP
Clinical Associate Professor
Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey
Long Branch, NJ
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times - speaker and medical writing honoraria, Otsuka Pharmaceuticals - Excel Speakers
Bureau (former, through March 2022), Novus Medical Education - consultant/medical writing, Boehringer Ingelheim - advisory board, Sunovion Pharmaceuticals –
consultant/advisory board, Biogen and Sage Therapeutics - advisory board
Monica Mathys, PharmD, BCGP, BCPP
Professor
Texas Tech University School of Pharmacy
Dallas, TX
Non-Financial Interests: AAPP Foundation Board member
Jessica L. Mulhollan, PharmD, BCPP
Clinical Pharmacy Specialist, Substance Use Disorders and Mental Health Clinical Pharmacy Supervisor
Louis Stokes Cleveland VA Medical Center
Cleveland, OH
No Relevant Financial Relationships to Disclose
Kristen Neumeister, PharmD, BCPP
Clinical Pharmacist
North Texas State Hospital
Fort Worth, TX
No Relevant Financial Relationships to Disclose
Megan O'Connell, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry and Neurology
Michigan Medicine
Ann Arbor, MI
No Relevant Financial Relationships to Disclose
Melissa C. Palmer, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist - Mental Health
Alaska VA Healthcare System
Anchorage, AK
No Relevant Financial Relationships to Disclose
Brittany L. Parmentier, PharmD, MPH, BCPS, BCPP
Clinical Pharmacy Specialist in Psychiatry
The Harris Center for Mental Health and IDD
Houston, TX
No Relevant Financial Relationships to Disclose
Jake R. Peters, PharmD, BCPP, BCPS
Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry
Butler University College of Pharmacy/Indiana University Health
Indianapolis, IN
No Relevant Financial Relationships to Disclose
Sarah J. Popish, PharmD, BCPP
VA PBM Academic Detailing Services, Program Manager
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: There is no FDA approved pharmacological treatment of Borderline Personality Disorder. All pharmacology discussion will be off-label. Generic terminology will be used whenever possible. Discussion of medication class (rather than mentioning an individual medication) will also be used when appropriate. This presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Cannabis, Cannabidiol (Epidiolex). This presentation will include brand names for some products to reduce confusion. My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Pharmacogenetic test results that are not mentioned in product labeling
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
System Update:
We are undergoing major upgrades right now, and we appreciate your patience.
If you need help, please use the support chat or email info@aapp.org.
Learn more.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 5 hours of ACPE credit and 5 hours of BCPP Recertification credit by successfully completing the online Clinical Application Series examination.